ROR1 靶向治療市場：目標表達譜、藥物模式安全性和有效性、管道審查和競爭格局分析

本報告研究了 ROR1 靶向治療市場，並提供了市場概況以及臨床趨勢、適應症和患者趨勢、競爭格局以及進入市場的公司概況。

內容

常用縮寫

第 0 章執行摘要

第一章目標背景：結構與功能

第 2 章目標抗原表達譜

• 血液系統惡性腫瘤
• 各種實體瘤
• 肺癌
• 胰腺癌
• 結腸癌
• 乳腺癌
• 卵巢癌

第 3 章 ROR1 靶向候選藥物的臨床前安全性

第 4 章 ROR1 靶向藥物治療的臨床經驗

第5章臨床適應症和患者人群

• 慢性淋巴細胞白血病
• 套細胞淋巴瘤
• 瀰漫性大 B 細胞淋巴瘤
• 三陰性乳腺癌

第 6 章競爭格局和藥物模式

• ROR1 靶向抗體-藥物偶聯物
• T 細胞結合抗 ROR1 抗體
• ROR1 靶向 CAR T 細胞和 NK 細胞的過繼性細胞療法
• ROR1小分子抑製劑

第 7 章藥物和細胞療法候選者簡介

• 裸抗體
• 抗體藥物偶聯物
• 涉及 T 細胞的雙特異性抗體
• CART 細胞和 NK 細胞
• 小分子抑製劑

第 8 章公司簡介

第 9 章參考文獻

This report evaluates Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1) from an industry perspective for its suitability as a tumor-specific target for cancer therapy based on its expression profile and preclinical and clinical safety and efficacy data of the various drug modalities employed for discovery and development of ROR1-targeted therapy candidates.

The report has identified the players in the field and presents a competitive landscape analysis of stakeholders and a pipeline review based on the specific profiles of drug candidates and companies active in the field. The report includes information about business transaction in the field, such as acquisitions, partnerships & collaborations and licensing deals. Furthermore, the financial background and situation of the key players is described.

Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a type I transmembrane protein that is physiologically expressed in early embryogenesis and plays a critical role in organogenesis. Expression of ROR1 attenuates rapidly after embryonic development, becoming virtually undetectable on post-partem tissues, with the exception of a few B cell precursors. In contrast, ROR1 is expressed on a variety of cancers, particularly those that are less differentiated, and is associated with early relapse after therapy or metastasis.

Because of its tumor-specific expression and potential functional significance, ROR1 has become of interest as a target for various drug modalities, especially with enhanced effector function. The most advanced molecules is currently being evaluated in potentially registrational phase II/III studies, but the majority of programs are in late preclinical and early clinical development, thus still offering opportunities for improvements.

This report is based information retrieved from proprietary database, clinical trial registries, abstracts, presentations and posters from scientific meetings as well as full publications, from company websites, press releases, SEC filings, investor and R&D presentations. The report was prepared in May/June of 2022 and was released on June 16, 2022.

What will you find in the report:

• The scientific rationale for ROR1-targeted therapies based on target characteristics and its differential expression profile;

• Preclinical safety of ROR1-targeted therapy candidates;

• Clinical experience and proof-of-concept with ROR1-targeted drug modalities;

• Clinical indications suitable for development of ROR1-targeted therapies and their patient populations;

• The competitive landscape of ROR1-targeted drug modalities in development;

• Specific profiles of ROR1-targeted drug modalities; and

• Profiles of companies active in the development of anti-ROR1 therapy candidates.

Table of Contents

Frequent Abbreviations

0. Executive Summary

1. Target Background: Structure & Function

2. Target Antigen Expression Profile

• 2.1. Hematologic Malignancies
• 2.2. Various Solid Tumors
• 2.3. Lung Cancer
• 2.4. Pancreatic Cancer
• 2.5. Colorectal Cancer
• 2.6. Breast Cancer
• 2.7. Ovarian Cancer

3. Preclinical Safety of ROR1-Targeted Therapy Candidates

4. Clinical Experience with ROR1-Targeted Drug Modalities

5. Clinical Indications & Patient Populations

• 5.1. Chronic Lymphocytic Leukemia
• 5.2. Mantle Cell Lymphoma
• 5.3. Diffuse Large B-Cell Lymphoma
• 5.4. Triple Negative Breast Cancer

6. Competitive Landscape & Drug Modalities

• 6.1. ROR1-Targeted Antibody Drug Conjugates
• 6.2. T-Cell EngagingAnti-ROR1 Antibodies
• 6.3. Adoptive Cell Therapy with ROR1-Targeted CAR T-Cells and NK Cells
• 6.4. ROR1 Small Molecule Inhibitor

7. Drug & Cell Therapy Candidate Profiles

• 7.1. Naked Antibody
• 7.2. Antibody-Drug Conjugates
• 7.3. T-Cell Engaging Bispecific Antibodies
• 7.4. CAR T-Cells & NK Cells
• 7.5. Small Molecule Inhibitor

8. Company Profiles

9. References

List of Tables

• Table 1: Overview of the Number of Cases of ROR1 Overexpression in Hematologic Malignancies
• Table 2: Overview of the Number of Cases of ROR1 Overexpression in Solid Tumors
• Table 3: Lead and Up-Side Indications of Clinical Studies with ROR1-Targeted Therapy Candidates
• Table 4: Overview of Number and R&D Stage of ROR1-Targeted Drug Modalities
• Table 5: Pipeline of ROR1-Targeted Antibody-Drug Conjugates in Development
• Table 6: Pipeline of T-Cell Engaging ROR1-Targeted Antibodies
• Table 7: Pipeline of ROR1-Targeted CAR T-Cells and NK Cells
• Table 8: NovalGen's ROR1-Targeted Drug Modality Pipeline